Key result
Mesalazine discontinuation resolves suspected drug-induced myopericarditis in ulcerative colitis.
Why the study?
Mesalazine-induced myopericarditis is a rare and unique complication in patients with ulcerative colitis that requires clinical recognition.
Case Report (n=1)
Mesalazine is a potential etiological factor for myopericarditis in patients with inflammatory bowel disease, and its discontinuation can lead to clinical improvement.
Answers are grounded in this paper and cite their sources.
Mesalazine may trigger myopericarditis in ulcerative colitis; this case report is hypothesis-generating and should not change practice.
A 25-year-old male with a background of ulcerative colitis presented with a two-week history of central chest pain. His ECG on presentation showed global T wave inversion with a peak troponin I of 165 ng/ml. Clinical diagnosis of myopericarditis/myocarditis was made. Echocardiography and cardiac MR confirmed the diagnosis. On detailed assessment of his medication history, mesalazine was suspected as an aetiological factor, with discontinuation resulting in an improvement in symptoms, inflammatory markers and cardiac enzymes. This is a unique case of mesalazine induced myopericarditis on a background of inflammatory bowel disease.
No takes yet. Share an insight, caveat, or question.
Asadi et al. (2017) conducted a case report in Ulcerative colitis, myopericarditis (n=1). Mesalazine was evaluated on Myopericarditis/myocarditis. Mesalazine exposure in a 25-year-old male with ulcerative colitis was suspected to induce myopericarditis, which improved upon discontinuation of the drug.
Synapse has enriched 10 related papers. Consider them for comparative context: